[go: up one dir, main page]

CL2023003652A1 - Nuevos profármacos y conjugados de dimetiltriptamina - Google Patents

Nuevos profármacos y conjugados de dimetiltriptamina

Info

Publication number
CL2023003652A1
CL2023003652A1 CL2023003652A CL2023003652A CL2023003652A1 CL 2023003652 A1 CL2023003652 A1 CL 2023003652A1 CL 2023003652 A CL2023003652 A CL 2023003652A CL 2023003652 A CL2023003652 A CL 2023003652A CL 2023003652 A1 CL2023003652 A1 CL 2023003652A1
Authority
CL
Chile
Prior art keywords
dimethyltryptamine
prodrugs
conjugates
new
pharmaceutically acceptable
Prior art date
Application number
CL2023003652A
Other languages
English (en)
Inventor
B Perni Robert
KHAN Tanweer
Short Glenn
Rao Srinivas
Original Assignee
Atai Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Atai Therapeutics Inc filed Critical Atai Therapeutics Inc
Publication of CL2023003652A1 publication Critical patent/CL2023003652A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

En la presente descripción se proporcionan compuestos de Fórmula (I), o sal farmacéuticamente aceptable de estos, en donde R1, R2, R3, R4, R5, R8, R9, X, Y, Z, W, y m se definen en la presente descripción. En la presente descripción también se proporcionan composiciones farmacéuticas que comprenden un compuesto de Fórmula (I) o sal farmacéuticamente aceptable de este y un excipiente farmacéuticamente aceptable.
CL2023003652A 2021-06-09 2023-12-06 Nuevos profármacos y conjugados de dimetiltriptamina CL2023003652A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163208874P 2021-06-09 2021-06-09
US202163229879P 2021-08-05 2021-08-05

Publications (1)

Publication Number Publication Date
CL2023003652A1 true CL2023003652A1 (es) 2024-05-17

Family

ID=84425491

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003652A CL2023003652A1 (es) 2021-06-09 2023-12-06 Nuevos profármacos y conjugados de dimetiltriptamina

Country Status (10)

Country Link
US (3) US20230041584A1 (es)
EP (1) EP4352043A4 (es)
JP (1) JP2024522174A (es)
KR (1) KR20240019152A (es)
AU (1) AU2022287974A1 (es)
CA (1) CA3221823A1 (es)
CL (1) CL2023003652A1 (es)
IL (1) IL309210A (es)
MX (1) MX2023014620A (es)
WO (1) WO2022261383A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
AU2022281358A1 (en) 2021-05-25 2023-11-23 Atai Therapeutics, Inc. New n,n-dimethyltryptamine salts and crystalline salt forms
MX2023014620A (es) 2021-06-09 2024-01-30 Atai Therapeutics Inc Nuevos profarmacos y conjugados de dimetiltriptamina.
WO2023108174A1 (en) * 2021-12-10 2023-06-15 Terran Biosciences, Inc. Analogs of 6-methoxy- n, n-dimethyltryptamine
US12012381B2 (en) 2021-12-30 2024-06-18 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023173196A1 (en) 2022-03-18 2023-09-21 Enveric Biosciences Canada Inc. C4-carboxylic acid-substituted tryptamine derivatives and methods of using
AU2023234202A1 (en) * 2022-03-18 2024-11-07 Enveric Biosciences Canada Inc. Salts of c4-carboxylic acid- and c4-carbonothioate-substituted tryptamine derivatives and methods of using
EP4633625A2 (en) * 2022-12-15 2025-10-22 ATAI Therapeutics, Inc. Prodrugs of dimethyltryptamine and derivatives thereof
WO2024227149A2 (en) * 2023-04-27 2024-10-31 Atai Therapeutics, Inc. Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines
CN116421600B (zh) * 2023-05-29 2024-08-23 重庆医科大学 色醇在制备治疗焦虑的药物中的应用
TW202525777A (zh) * 2023-08-25 2025-07-01 英商康派斯開拓者公司 ３－（２－（二甲基胺基）乙基）－１ｈ－吲哚－４－基衍生物

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1164828A (en) 1965-10-23 1969-09-24 Robins Co Inc A H 3-(2-Substituted Ethyl)Indoles and their Manufacture and Use
US5340838A (en) 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
JP3361836B2 (ja) 1991-07-04 2003-01-07 三共株式会社 アミノ酸誘導体
FR2691145A1 (fr) 1992-05-18 1993-11-19 Inst Nat Sante Rech Med Nouveaux dérivés de la dihydroxybenzylamine, leur préparation et les compositions pharmaceutiques qui les contiennent.
GB9226532D0 (en) 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
CA2147991A1 (en) 1993-09-01 1995-03-09 Richard A. Glennon Tryptamine analogs with 5-ht1d selectivity
CA2207201A1 (en) 1994-12-06 1996-06-13 Caroline Henry Azetidine, pyrrolidine and piperidine derivatives as 5ht1 receptor agonists
US6436950B1 (en) 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
DE69922676T2 (de) 1998-10-07 2005-12-15 Ortho-Mcneil Pharmaceutical, Inc. N-aralkylaminotetraline als neuropeptid-y-y5-rezeptorliganden
ES2272252T3 (es) 1999-01-14 2007-05-01 Teijin Limited Dispositivo para administrar una cantidad constante de un cuerpo en polvo.
GB0114272D0 (en) 2001-06-12 2001-08-01 Optinose As Nasal delivery device
JP4543553B2 (ja) 1999-03-03 2010-09-15 オプティノーズ アズ 鼻用の送り込み装置
GB0121568D0 (en) 2001-09-06 2001-10-24 Optinose As Nasal delivery device
DK1202986T3 (da) 1999-07-28 2006-02-20 Ortho Mcneil Pharm Inc Amin- og amidderivater som ligander for neuropeptid Y-Y5-receptoren, der er nyttige ved behandlingen af obesitet og andre lidelser
DE10007948A1 (de) 2000-02-22 2001-09-06 Wella Ag Mittel zur Färbung von Fasern
GB0019715D0 (en) 2000-08-10 2000-09-27 Pa Consulting Services Device for delivering physiologically active agent in powdered form
ZA200306564B (en) 2001-02-26 2004-10-15 Optinose As Nasal devices.
KR100894189B1 (ko) 2001-03-29 2009-04-22 일라이 릴리 앤드 캄파니 5-ｈｔ6 수용체의 길항제로서의 ｎ-(2-아릴에틸)벤질아민
ITRM20010356A1 (it) 2001-06-21 2002-12-23 Sigma Tau Ind Farmaceuti "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina.
US20050245594A1 (en) 2001-06-29 2005-11-03 Sutter Diane E Dermal delivery of anti-pain agents and methods useful thereof
JP4795637B2 (ja) 2001-09-28 2011-10-19 カーブ テクノロジー，インコーポレイティド 鼻ネブライザー
EP1336602A1 (en) 2002-02-13 2003-08-20 Giovanni Scaramuzzino Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
GB0207422D0 (en) 2002-03-28 2002-05-08 Optinose As Nasal devices
GB0207817D0 (en) 2002-04-04 2002-05-15 Optinose As Nasal devices
GB0209494D0 (en) 2002-04-25 2002-06-05 Optinose As Nasal devices
US20050152858A1 (en) 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
WO2005112921A2 (en) 2004-04-26 2005-12-01 Vanderbilt University Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity
WO2006099416A1 (en) 2005-03-11 2006-09-21 Nitromed, Inc. 2-methyl indole cyclooxygenase-2 selective inhibitors, compositions and methods of use
US20080248511A1 (en) 2007-03-26 2008-10-09 Promega Corporation Methods to quench light from optical reactions
CA2686994A1 (en) 2007-05-11 2008-11-20 Mpex Pharmaceuticals, Inc. Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof
WO2009049030A1 (en) 2007-10-09 2009-04-16 Triton Biopharma, Llc Method to use compositions having antidepressant anxiolytic and other neurological activity and compositions of matter
EP2340242A4 (en) 2008-10-22 2012-04-04 Acucela Inc COMPOUNDS FOR THE TREATMENT OF EYE DISEASES AND DRESSES
WO2010151258A1 (en) 2009-06-24 2010-12-29 The Board Of Regents Of The University Of Oklahoma Methods of treating psychological conditions
WO2011041870A1 (en) 2009-10-07 2011-04-14 Nitrogenix Inc. Non-steroidal anti-inflammatory drugs coadministered with nitric oxide amino acid ester compounds as prophylaxis in hypertensive patients
EP2418196A1 (en) 2010-07-29 2012-02-15 IMTM GmbH Dual alanyl-aminopeptidase and dipeptidyl-peptidase IV inhibitors
WO2013063492A1 (en) 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
WO2013142770A1 (en) 2012-03-23 2013-09-26 Codexis, Inc. Biocatalysts and methods for synthesizing derivatives of tryptamine and tryptamine analogs
CA2868362C (en) 2012-03-29 2018-07-31 Jerome Schentag Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
WO2014134127A1 (en) 2013-02-26 2014-09-04 Northeastern University Cannabinergic nitrate esters and related analogs
GB201409516D0 (en) 2014-05-29 2014-07-16 Randox Lab Ltd Immunoassay for compounds of the NBOMe family
US20220079881A1 (en) 2016-03-03 2022-03-17 Ctt Pharma Inc. Orally Administrable Composition
US20190358238A1 (en) 2016-11-16 2019-11-28 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
WO2018094005A1 (en) 2016-11-16 2018-05-24 The General Hospital Corporation Myeloperoxidase imaging agents
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US11723894B2 (en) 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
WO2019099402A1 (en) 2017-11-14 2019-05-23 Rutgers, The State University Of New Jersey Therapeutic compounds and methods to treat infection
EP3762498A4 (en) 2018-03-08 2022-03-09 New Atlas Biotechnologies LLC PROCESS FOR PRODUCTION OF TRYPTAMINE
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Methods of treating substance abuse
WO2020037372A1 (en) 2018-08-22 2020-02-27 University Of Technology Sydney Nbome test
US20220031662A1 (en) 2019-02-22 2022-02-03 GH Research Ireland Limited Compositions comprising 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) for use in treating mental disorders
AU2020225410B2 (en) 2019-02-22 2025-10-30 GH Research Ireland Limited 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) for treating depression
AU2020228289A1 (en) 2019-02-27 2021-09-09 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
EP4219498A1 (en) 2019-03-07 2023-08-02 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic / psychotomimetic dosages and formulations
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
CA3146050A1 (en) 2019-07-04 2021-01-07 Sw Holdings, Inc. Metered dosing compositions and methods of use of psychedelic compounds
AU2020381103B2 (en) 2019-11-07 2022-08-11 Cybin Uk Ltd Compounds
US11660305B2 (en) 2019-11-19 2023-05-30 Turtle Bear Holdings, Llc Tryptamine compositions for enhancing neurite outgrowth
CA3281662A1 (en) 2020-02-05 2025-11-29 Yale University Psychedelic treatment for headache disorders
US11332441B2 (en) 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
AU2021268204A1 (en) 2020-05-08 2022-12-08 Psilera Inc. Novel compositions of matter and pharmaceutical compositions
AU2021276656A1 (en) 2020-05-19 2022-11-24 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
EP3902541B1 (en) 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
BR112022025306A2 (pt) 2020-06-12 2023-02-28 Beckley Psytech Ltd Composição compreendendo um sal benzoato de 5-metóxin, n-dimetiltriptamina
WO2022051670A1 (en) 2020-09-04 2022-03-10 Gilgamesh Pharmaceuticals, Inc. Azetidinyl tryptamines and methods of treating psychiatric disorders
CA3192617A1 (en) 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement
WO2022082058A1 (en) 2020-10-16 2022-04-21 Eleusis Therapeutics Us, Inc. Method of treatment by tryptamine alkaloids
KR20240000516A (ko) 2021-04-26 2024-01-02 아타이 테라퓨틱스, 인크. 신규 n,n-디메틸트립타민 조성물 및 방법
WO2022235529A1 (en) 2021-05-03 2022-11-10 Mind Medicine, Inc. Method of titrating dose of psychedelics
US20220354862A1 (en) 2021-05-04 2022-11-10 Mind Medicine, Inc. Liposome delivery of psychedelics
AU2022281358A1 (en) 2021-05-25 2023-11-23 Atai Therapeutics, Inc. New n,n-dimethyltryptamine salts and crystalline salt forms
JP2024520017A (ja) 2021-05-26 2024-05-21 マインドセット ファーマ インコーポレイテッド 幻覚剤と脂肪酸との併用
MX2023014620A (es) 2021-06-09 2024-01-30 Atai Therapeutics Inc Nuevos profarmacos y conjugados de dimetiltriptamina.
EP4398871A1 (en) 2021-09-08 2024-07-17 Cybin IRL Limited Combination drug therapies
EP4408412A4 (en) 2021-09-30 2025-07-16 ATAI Life Sciences AG COMPOSITIONS AND METHODS FOR TREATING HEADACHES
US20230310374A1 (en) 2021-09-30 2023-10-05 ATAI Life Sciences AG Compositions and methods for treating headache or facial pain
EP4457222A4 (en) 2021-12-28 2025-12-24 Empathbio Inc MDA AND MDMA NITRIC OXIDE-RELEASING PROMEDICAMENTS
US12012381B2 (en) 2021-12-30 2024-06-18 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs

Also Published As

Publication number Publication date
US11643391B2 (en) 2023-05-09
EP4352043A1 (en) 2024-04-17
CA3221823A1 (en) 2022-12-15
US20230357146A1 (en) 2023-11-09
EP4352043A4 (en) 2025-06-25
KR20240019152A (ko) 2024-02-14
MX2023014620A (es) 2024-01-30
AU2022287974A1 (en) 2024-01-04
US20230066720A1 (en) 2023-03-02
IL309210A (en) 2024-02-01
US12065405B2 (en) 2024-08-20
WO2022261383A1 (en) 2022-12-15
US20230041584A1 (en) 2023-02-09
JP2024522174A (ja) 2024-06-11

Similar Documents

Publication Publication Date Title
CL2023003652A1 (es) Nuevos profármacos y conjugados de dimetiltriptamina
CO2024001367A2 (es) Compuestos antivirales
PE20251288A1 (es) Compuestos heterociclicos como inmunomoduladores
AR106944A2 (es) Compuestos de isoindolina y composiciones farmacéuticas de los mismos
CR20220638A (es) Derivados de amidopirimidona
MX2022012240A (es) Metilacion de compuestos mcl-1.
CO2021014210A2 (es) Compuestos de pirrol
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
HRP20050390A2 (en) Substituted benzoxazinones and uses thereof
CL2021003139A1 (es) Compuestos tricíclicos
MX2024011179A (es) Compuestos multiciclicos
CO2023002940A2 (es) Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CR20240203A (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
CO2024010726A2 (es) Compuestos heterocíclicos y métodos de uso
DOP2024000077A (es) Compuestos de cd73
UY38567A (es) Inhibidores de o-glucoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa de éter bicíclico
AR044320A1 (es) Derivados 3-decladinosilo de la clase de 9a - n-carbamoil - y 9a-ntiocarbamoil- 9 dihidro-9a aza- 9a - homoeritromicina a
PE20250457A1 (es) Compuestos antivirales y metodos de elaboracion y uso de los mismos
CL2022002106A1 (es) Moduladores de nampt.
AR124720A1 (es) Derivados de pirazolamida
AR133855A1 (es) Compuestos de amina sustituida, composiciones y métodos de uso
CO2024018265A2 (es) Compuestos de cd73
FI20022159A0 (fi) Uusia farmaseuttisia yhdisteitä
AR127559A1 (es) Compuestos, composiciones y métodos
AR126834A1 (es) Profármacos y derivados de psilocina y usos de estos